The analysis of some extra-and intragenic markers within or closely linked to the cystic fibrosis transmembrane regulator (CFTR) gene is useful as a molecular method in clinical linkage analysis. Indeed, knowing that the molecular basis of cystic fibrosis (CF) is highly heterogeneous in our population, the study of haplotype association with normal and CF chromosomes could be very helpful in cases where one or both mutations remain unidentified. In this study, we analysed with PCR-RFLP and capillary electrophoresis some extra (pJ3.11, KM19 and XV2C) and intragenic (IVS8CA, IVS17bTA and IVS17bCA) polymorphic markers in 50 normal and 10 Tunisian patients carrying the rare E1104X mutation in order to determine the haplotype associated with this mutation. For the extragenic markers, 8 haplotypes were identified. The most frequent of them are the 221 and 112 accounting for 80% of total haplotypes. For the intragenic markers, five haplotypes were present on the E1104X chromosomes. One of them 16-31-13 accounted for 50%. To our knowledge, this is the first work to be interested to the haplotypes linked to the E1104X mutation. This preliminary study of haplotypes could be a helpful method to determine the molecular lesions responsible of this pathology.
Cystic fibrosis (CF) is the most common lethal autosomal recessive disorder in Caucasian populations. The gene responsible for this disease, encodes a 1480 amino-acid protein called the cystic fibrosis transmembrane conductance regulator CFTR (13) . Numerous mutations on this gene have been identified to be responsible for CF.
The most common defect is observed to be the F508 del mutation, deletion of 3 base pair in exon 10 . In Tunisian population, 12 different CFTR mutations, accounting for 90% of CF alleles, have been found. The E1104X located in exon 17b, is the second mutation after the F508del mutation in our population, represents 16 .18% of all CF mutations but it is a rare mutation in the world (9) .
In populations with heterogeneous spectrum mutations, genetic analysis can be facilitated by haplotype study.
The haplotypes associated with the CFTR mutations in the North African population remain unidentified. In this work we aimed to determine haplotypes associated with the E1104X mutation using 3 intragenic microsatellites (IVS8CA, IVS17bTA and IVS17bCA), and 3 extragenic markers (pJ3.11, KM19 and XV2C). The combination of both types of markers is expected to provide useful information regarding the origin and evolution of CFTR mutations (20) .
Association of haplotype with a specific CFTR mutation would help to increase genetic informativity for prenatal diagnosis and carrier detection in many of studied families where one or no mutations are known.
Materials and Methods
This study included 10 CF pediatric patients, aged between 2 and 18 months. The selection was based on typical clinical manifestations of pulmonary and/or gastro-intestinal disease and high levels of sweat chloride concentration (higher than 60 mmol/l). The CFTR mutation was previously identified to be the E1104X mutation using DGGE and sequencing reaction (9) .
A control group consisting of 50 healthy non-CF patients, aged between 2 months and 4 years, was also studied.
All CF children and healthy controls parents participating in this study were informed in details about the study and informed consents were signed.
Genomic DNA of studied samples was extracted from peripheral blood with the classical salting-out protocol (16) .
RFLP analysis
Extragenic markers (pJ3.11, KM19 and XV2C) were analyzed with restriction fragment length polymorphism (RFLP) procedure.
The pJ3.11 marker is located at 750 Kb of the 3' end of the CFTR gene (6), the XV2C and KM19 markers are located 175 and 125 Kb up stream of the 5' end of the CFTR gene (22) .
RFLP allows to discriminate between two alleles at each marker based on the presence or the absence of a restriction site.
DNA was amplified using sequence primers previously described. (Table I ) (6, 22) . To analyze XV2C marker, the products were digested by TaqI restriction enzyme (22) . For pJ3.11 and KM19 markers, amplified products were analyzed by PstI restriction enzyme (14, 22) . PCR and restriction products were separated by electrophoresis on 2% agarose gel.
The extragenic haplotype construction was established using the standard nomenclature; the absence of the restriction site (-) corresponds to allele 1, and the presence of the restriction (+) site corresponds to allele 2 (8). 
Multiplex PCR Intragenic markers IVS8CA (intron8), IVS17bTA and IVS17bCA (intron 17b) were analyzed by a multiplex PCR reaction. PCR were performed with 200 ng of DNA, 1X Master Mix (Promega) and 10 pmoles of each primer with fluorescent Hex or Fam phosphoramidites in a total volume of 14 µl. The primer sequences was previously described (Table I) (17, 26) . 
Capillary electrophoresis

Statistical analysis
Chi-square test was used to compare the haplotype association among CF patients and healthy individuals.
Results and Discussion
The E1104X mutation, initially discovered by Zielenski in a French-Canadian patient in 1992 (http://www.genet.sickkids.on.ca/cftr/), consists of a single nucleotide substitution (G to T) at position 3442 in exon 17b, and causes introduction of a premature stop codon (GAA to TAA) at position 1104 in the protein sequence (27) .
The E1104X mutation was later described in Germany by Reiss in 1993 (21) , in France (4, 23, 24) , and in US (10) .
This mutation is considered rare in the wordwide CF population but seems to be more frequent in our population with 16.18% of CF chromosomes (9) .
The study of extragenic haplotypes associated with the E1104X allele revealed 8 different haplotypes (Table II) . Five of them were found in CF chromosomes as well as in normal ones (Table II) . The other three haplotypes were encountered solely in healthy individuals.
The 221 and 112 haplotypes accounting, respectively, for 45% and 35% of CF chromosomes haplotypes were significantly more frequent in this group than in healthy individuals (p = 0.00019, 0.006 respectively) ( Table II) .
Analysis of intragenic haplotypes established with microsatellites markers IVS8CA, IVS17bTA and IVS17bCA are shown in Table III .
For the 120 analyzed chromosomes, 42 different haplotypes were described. Five haplotypes were observed in E1104X chromosomes. One of them (16-31-13) , accounting for 50%, was strongly associated to this mutation (p = 6. 4 10 -11 ) (Table III) . Haplotype is named according to the absence (1) or presence (2) of restriction site at loci pJ3.11, KM19 and XV2C, respectively A second haplotype (16-30-13) present only in CF chromosomes representing 20% appears also to be highly associated with this mutation (p = 0.00038) (Table III) . Two other less frequent haplotypes (16-30-14 and 16-29-14) show significant association with CF chromosomes (p = 0.013 and 0.018 respectively) ( Table III) .
The multiple allelism of CF prevents the rapid and reliable diagnosis of the diseasecausing mutations in compound heterozygotes and non-F508del homozygotes. Knowledge of the population genetics and the chromosomal marker haplotype of the various CFTR mutations would significantly facilitate the mutation diagnosis in CF.
Microsatellites and single nucleotide polymorphisms (SNPs) have been described within the CFTR gene. Both types of markers can be used to trace the origin and evolution of the different CF mutations (1, 18, 19, 25) . SNPs can be used to define the stable haplotypic frameworks on which CFTR mutations occurred. Microsatellite markers, which mutate faster and that are more diverse among chromosomes, can help to measure genetic variability within the CFTR locus and to estimate the age of CF mutations (1, 7, 15, 26) .
The most common CF mutations (F508del, G542X and N1303K), provide an exceptional opportunity for the analysis of association between microsatellite allelic systems and SNP's. The patterns of haplotypes associated with these mutations should help in the understanding of the evolution of microsatellite loci and should help to define the anthropological time of the mutation (10). However, the haplotype analysis linked to rare mutation remains undetermined, that is why in this study we aimed to determine haplotypes associated with the E1104X mutation using some extra (pJ3.11, KM19 and XV2C) and intragenic (IVS8CA, IVS17bTA and IVS17bCA) polymorphic markers. We opted to combine six different markers for better informativity and for their strong association with CFTR gene (Fig. 1) .
Our work is the first in the world to be interested to the study of the haplotype linked to the E1104X mutation. In fact, this mutation was observed in different populations from Canada, France, Germany and the US, with a low frequency excepted in Tunisian and Libyan populations where it represents 16.18% and 40%, respectively, of CFTR spectrum mutation (9, 11) . We found it interesting to determine haplotypes associated with the E1104X mutation to provide information on the age and origin of this mutation.
Oueslati S et al. Statistical analysis showed difference between haplotypes distribution in normal and CF chromosomes. For the extragenic haplotype, E1104X mutation is associated in 80% of cases to both 221 and 112 haplotypes. However, these two haplotypes were observed only in 20% of normal population chromosomes (p = 0.00019, 0.006, respectively) ( Table II) .
The E1104X mutation revealed a heterogeneous microsatellite polymorphism profile since it was associated with five different haplotypes. The most frequent microsatellites haplotype 16-31-13 is found only in one chromosome of normal population (p = 6.4 10 -11 ) (Table III) . This association can help considerably in mutation analysis by using microsatellite markers after screening for F508del.
The 16-31-13 haplotype found in 50% of E1104X chromosomes was also described linked to 2 rare mutations, the E60X mutation in UK (12) and S549N mutation in the "Grande briére" population (3). Association of the same haplotype with these 3 mutations suggest a common origin.
The 23-31-13 haplotype generally associated with the most common mutation F508del (2, 5), was not encountered in the E1104X chromosomes. However, the similarity on the IVS17bTA and IVS17bCA markers between this haplotype and the 16-31-13 haplotype would also suggest a common ancestral genetic background on which both mutations arose.
On the other hand, the 16-30-13 and 16-30-14 haplotypes not observed in the normal chromosomes could be suggested as specific and sensitive haplotypes for E1104X mutation.
The 16-30-13, 16-30-14 and 16-29-14 haplotypes seem to derive from the 16-31-13 one as a result of a slippage at the IVS17bTA and/or IVS17bCA markers which thus suggesting a fonder effect.
In our country 9.56% of CFTR mutations remain indetermined (27) . In this case a combination of methods for mutation detection and haplotype analysis could provide rapid, accurate, and reliable information especially in prenatal diagnosis for couples at risk of having a child affected with cystic fibrosis. 
